PKM and cancer: It is recently reported that in non-small cell lung cancer (NSCLC), hypoxia-induced exosomes by the cisplatin-resistant cancer cells can deliver pyruvate kinase M2 (PKM2), a key mediator in the process of cancer cells converting glucose into lactic acid [47], to CAFs, leading to the release of pyruvate and lactate and subsequent chemoresistance [48].